Phase1, Quantitative Bioanalytics

About your role

Phase1 is Orion's paid trainee programme designed for university students, bringing together a large and diverse group of talents from various fields every year. In addition to interesting summer jobs with meaningful projects, the programme offers a variety of events, networking opportunities with other Phase1 Trainees and Orion employees, as well as small group mentoring to support your career Could this be the first research phase of your Orion career? You can find more information about the Phase1 trainee programme on Orion's website .

Are you a university student in the final stages of your studies and passionate about bioanalytics? Join our Quantitative Bioanalytics Unit as a Phase1 Trainee and gain hands-on experience in developing cutting-edge bioanalytical methods for biologics.

Your key responsibilities

• Method Development: Design and implement robust LC-MS and/or ligand binding assay (LBA) methods for quantitative analysis of biotherapeutics.
• Sample Preparation: Develop and optimize biological sample pretreatment workflows for accurate quantification.
• Automation & Innovation: Utilize advanced tools such as pipetting robots to establish automated analytical processes.
• Hands-On Lab Work: Prepare biological samples and perform analyses using state-of-the-art instrumentation.

What we offer

• Training & Growth: Learn about drug development in the pharmaceutical industry and gain expertise in modern bioanalytical techniques.
• Cutting-Edge Technology: Work with advanced LC-MS systems, LBA platforms, and automation tools.
• Collaborative Environment: Join a team of skilled professionals and contribute to impactful projects in biotherapeutics.
• Support from our experts: you are working in a team which will support you by all way.

At Orion, your work creates true impact and well-being for our customers, patients and society at large. Our culture of friendliness, respect, mutual appreciation and diversity creates a safe working environment where you can strive for excellence. We offer a wealth of career paths and development opportunities that support the development of innovative solutions and improving the quality of life.

Please visit our website to find further information about our values and Orion as an employer

Our expectations

• A university student in the late phase of studies (e.g., pharmacy, biotechnology, chemistry, or related field).
• Passion in bioanalytical method development and hands-on laboratory work.
• Basic understanding of biotherapeutics (antibodies) and analytical instruments/methods in LC-MS and/or LBA.
• Experience in laboratory work in your studies or in your earlier work positions.
• Motivation to learn and contribute in a dynamic research environment.
  Good communication skills in English

How to apply and additional information

Please apply as soon as possible, but no later than February 1st, 2026. We might start interviewing candidates during the application time, so please ensure that we have your application as soon as possible

For more details on the position, please contact Mika Pykäläinen (Head of Quantitative Bioanalytics & Biomarkers) tel Available for calls on 1 3 January ( 12:00-1 3:00 ) and 1 6 January ( 12:00 -1 4:00 ).

Our Phase1 trainees will be paid a monthly salary of €2370–2625, depending on the number of completed study credits. In addition, the Phase1 trainees are eligible to various employee benefits offered by the company.

If you would like to know more about the application process and timelines, please visit our website .

Welcome to build well-being with us next summer 2026

Approved medical examination which also includes drug testing is required prior to the employment . We will also carry out a security clearance prior to the employment for the selected person.

Unit description

Orion's pharmaceutical innovations are created within its R&D organization. We employ around 400 top professionals in the field of drug discovery and development. We work globally: in Espoo and Turku in Finland, in Nottingham and Cambridge in England and in New York, NY, USA. Orion R&D and the Innovative Medicines business division are dedicated to making a transformation to become a global player in the pain and oncology therapy areas.

The Quantitative Bioanalytics & Biomarkers unit is part of the Integrated DMPK and Safety at Orion R&D. The unit is responsible for quantitative bioanalysis from early discovery to clinical phases, focusing on developing and validating bioanalytical methods to quantify drugs, metabolites, and biomarkers in biological fluids, tissues and in vitro samples and implementing methods in use. We work with small molecules (SME) as well with biologics supporting our oncology and pain therapeutics areas.